Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Deferred Taxes (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Deferred Taxes for 15 consecutive years, with -$10.6 million as the latest value for Q4 2025.

  • Quarterly Deferred Taxes fell 183.29% to -$10.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$22.7 million through Dec 2025, down 243.57% year-over-year, with the annual reading at -$22.7 million for FY2025, 243.57% down from the prior year.
  • Deferred Taxes hit -$10.6 million in Q4 2025 for Ligand Pharmaceuticals, up from -$21.3 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $20.7 million in Q2 2024 to a low of -$46.3 million in Q4 2022.
  • Historically, Deferred Taxes has averaged -$1.5 million across 5 years, with a median of -$606000.0 in 2021.
  • Biggest YoY gain for Deferred Taxes was 922.71% in 2022; the steepest drop was 12000.51% in 2022.
  • Year by year, Deferred Taxes stood at $389000.0 in 2021, then tumbled by 12000.51% to -$46.3 million in 2022, then skyrocketed by 89.34% to -$4.9 million in 2023, then surged by 357.18% to $12.7 million in 2024, then crashed by 183.29% to -$10.6 million in 2025.
  • Business Quant data shows Deferred Taxes for LGNDZ at -$10.6 million in Q4 2025, -$21.3 million in Q3 2025, and $325000.0 in Q2 2025.